Trametinib is a MEK inhibitor used in the treatment of melanomas with BRAFV600E/K mutations [81], Cobimetinib is a MEK inhibitor used in combination with Vemurafenib for the treatment of advanced melanoma [82], Selumetinib is used in tumors with NRAS mutations and in radioiodine-refractory thyroid carcinomas [83], while Binimetinib has shown potential in melanomas and other KRAS/NRAS-mutant solid tumors [84]. This evidence concerns the gene MAP2K7 and thyroid gland carcinoma.